Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ:NTRA) received PMDA regulatory approval in Japan for its Signatera molecular residual disease (MRD) test in the adjuvant treatment setting for colorectal cancer (CRC). Signatera becomes the first PMDA-approved MRD test in Japan, backed by the 2,240-sample GALAXY trial and JSCO/JSMO guidance. Commercial launch in CRC is expected by the end of 2026, subject to final pricing, via exclusive partner SRL and its nationwide lab network.
Natera (NASDAQ:NTRA) announced that the National Comprehensive Cancer Network has updated its Bladder Cancer Guidelines to include tumor-informed multiplex PCR ctDNA-based MRD testing for muscle-invasive bladder cancer (MIBC).
The update grants a Category 1 recommendation for Signatera-guided adjuvant atezolizumab in MRD-positive patients within one year post-cystectomy and recognizes personalized ctDNA-MRD as a prognostic and predictive biomarker in MIBC. Signatera was the MRD assay used in the Phase 3 IMvigor011 trial, and in May 2026 the FDA approved Signatera CDx as a companion diagnostic for MIBC patients who may benefit from adjuvant immunotherapy.
Natera (NASDAQ:NTRA) will showcase its organ health portfolio at the American Transplant Congress, June 20-24, 2026. The company and collaborators plan 21 presentations, including seven oral talks, emphasizing the Prospera dd-cfDNA test for kidney, heart, lung and multi-organ transplant monitoring.
Featured data include PEDAL and ProActive study analyses linking Prospera levels to graft stability, rejection risk and adverse outcomes.
Natera (NASDAQ:NTRA) and CytoDyn (OTCQB:CYDY) announced a strategic collaboration on June 4, 2026 to support leronlimab development in metastatic colorectal cancer (mCRC).
Natera will use its personalized MRD assay Signatera and a large real-world molecular oncology dataset to analyze ctDNA dynamics in samples from CytoDyn’s CLOVER Phase 2 mCRC study.
Natera (NASDAQ:NTRA) appointed leading oncologists Thomas Lynch, M.D. and Eric Rubin, M.D. to its board of directors, effective June 3, 2026.
Dr. Lynch joins the Human Capital Committee, while Dr. Rubin joins the Nominating, Corporate Governance and Compliance Committee, adding extensive oncology, clinical development and precision medicine expertise.
Natera (NASDAQ:NTRA) announced a collaboration with Diakonos Oncology to use its personalized MRD assay Signatera in the DOC-RM Phase I/II trial in refractory melanoma. The study evaluates investigational dendritic cell therapy DOC1021 (dubodencel), which has FDA Fast Track designation in unresectable or metastatic cutaneous melanoma.
Signatera will longitudinally measure circulating tumor DNA at multiple timepoints to assess molecular response and disease dynamics in this high unmet-need population.
Natera (NASDAQ:NTRA) has enrolled the first patients in SIGNAL-ER 101, a prospective, single-arm, multi-center study using Signatera to guide de-escalation of adjuvant CDK4/6 inhibitor therapy in intermediate-risk, HR+/HER2- early breast cancer.
The trial plans to enroll ~725 patients at 50 U.S. sites, assigning CDK4/6 inhibitors based on MRD status and quarterly Signatera monitoring.
Natera (NASDAQ:NTRA) announced an enhanced Panorama NIPT powered by SNP-informed deep sequencing, aimed at improving performance in low fetal fraction samples.
A prospective, blinded study in 3,323 patients, including 242 low fetal fraction or previously no-call samples, showed 100% sensitivity for trisomy 21 and 13, 93.3% for trisomy 18, and a reduced no-call rate of 0.5%, with all outcomes confirmed by diagnostic genetic testing.
Natera (NASDAQ:NTRA) will present 35 oncology studies, including 3 oral talks, at the 2026 ASCO meeting in Chicago.
Data feature Signatera-based MRD testing in colorectal cancer, a large pan-cancer meta-analysis, ultrasensitive phased variant technology across solid and blood cancers, plus new real-world evidence and an Annotation digital platform.
Natera (NASDAQ:NTRA) announced a major expansion at its North Austin headquarters, adding a dedicated sequencing facility and new lab space to support rapid growth.
The facility is expected to have the largest sequencing capacity in the world, meeting rising demand, especially in oncology, where testing volumes grew over 54% year-over-year in Q1 2026.
Natera’s Signatera test is used by more than 50% of U.S. oncologists, and Signatera CDx recently became the first FDA-approved companion diagnostic in molecular residual disease testing. The expansion is expected to create up to 400 new jobs across professional, laboratory, and operational roles while supporting hundreds of ongoing clinical trials and research collaborations.